产品中心 抗体 其他一抗

Phospho-Met (Tyr1234/1235) Recombinant Rabbit mAb (S-3260)

Hepatocyte growth factor receptor,HGF/SF receptor,Proto-oncogene c-Met,Scatter factor receptor (SF receptor),Tyrosine-protein kinase Met,MET

价格 600.00 供应商现货 : 3-5个工作日
货号 S0B6873
规格
数量
收藏 分享

产品介绍 评论(0)

产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    Phospho-Met (Tyr1234/1235)
  • 分子别名

    Hepatocyte growth factor receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor (SF receptor); Tyrosine-protein kinase Met; MET
  • 细胞定位

    Membrane
  • Accession

    P08581
  • 克隆号

    S-3260
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 反应种属 ?

    Hu, Ms, Rt
  • 纯化方式

    Protein A
  • 浓度

    0.5 mg/ml
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt / reconstitution, -20 °C as supplied

  • 应用

    WB

  • 稀释度

    应用 稀释度 推荐种属
    WB 1:1000 Hu, Ms, Rt
背景介绍
  • Phospho-Met (Tyr1234/1235) refers to the activated form of the c-Met receptor tyrosine kinase, a critical transmembrane protein encoded by the MET proto-oncogene, wherein phosphorylation at tyrosine residues 1234 and 1235 within the intracellular kinase activation loop serves as a definitive molecular switch for its enzymatic activity. This specific dual phosphorylation event is induced upon binding of its primary ligand, hepatocyte growth factor (HGF), leading to conformational changes that stabilize the active kinase state, thereby facilitating downstream signal transduction through major pathways such as PI3K/Akt, RAS/MAPK, and STAT, which collectively regulate essential cellular processes including proliferation, survival, motility, and morphogenesis. Due to its pivotal role in tissue regeneration and embryonic development, as well as its frequent dysregulation in various malignancies where it drives tumor growth, invasion, and metastasis, Phospho-Met (Tyr1234/1235) is widely utilized as a specific biomarker in research and clinical diagnostics to monitor c-Met pathway activation and to evaluate the efficacy of targeted therapeutic inhibitors designed to block this oncogenic signaling axis.

评论(0)